Lumigan

RSS

bimatoprost

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 26/04/2019

Authorisation details

Product details
Name
Lumigan
Agency product number
EMEA/H/C/000391
Active substance
bimatoprost
International non-proprietary name (INN) or common name
bimatoprost
Therapeutic area (MeSH)
  • Glaucoma, Open-Angle
  • Ocular Hypertension
Anatomical therapeutic chemical (ATC) code
S01EE03
Publication details
Marketing-authorisation holder
Allergan Pharmaceuticals Ireland
Revision
31
Date of issue of marketing authorisation valid throughout the European Union
08/03/2002
Contact address
Castlebar Road
Westport, Co Mayo
Ireland

Product information

26/03/2019 Lumigan - EMEA/H/C/000391 - N/0058

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • Ophthalmologicals

  • prostaglandin analogues

Therapeutic indication

Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers).

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating